This site is intended for Healthcare professionals only.

Lupin receives USFDA nod for generic Namenda XR Capsules


Lupin receives USFDA nod for generic Namenda XR Capsules

Pharma Major Lupin Limited announced that it has received final approval for its Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg from the United States Food and Drug Administration (FDA) to market a generic version of Allergan’s Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg.

Lupin’s Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg are the AB rated generic equivalent of Allergan’s Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg.

Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg are indicated for treatment of moderate to severe dementia of the Alzheimer’s type. Namenda XR Capsules had US sales of USD 1.22 Billion



Source: Press Release
0 comment(s) on Lupin receives USFDA nod for generic Namenda XR Capsules

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted